<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339976</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>The Omicron Variant Is Associated with a Reduced Risk of the Post COVID-19 Condition and Its Main Phenotypes Compared to the Wild-Type Virus: Results from the EuCARE-POSTCOVID-19 Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1500</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091500</ELocationID><Abstract><AbstractText>Post COVID-19 condition (PCC) is defined as ongoing symptoms at &#x2265;1 month after acute COVID-19. We investigated the risk of PCC in an international cohort according to viral variants. We included 7699 hospitalized patients in six centers (January 2020-June 2023); a subset of participants with &#x2265;1 visit over the year after clinical recovery were analyzed. Variants were observed or estimated using Global Data Science Initiative (GISAID) data. Because patients returning for a post COVID-19 visit may have a higher PCC risk, and because the variant could be associated with the probability of returning, we used weighted logistic regressions. We estimated the proportion of the effect of wild-type (WT) virus vs. Omicron on PCC, which was mediated by Intensive Care Unit (ICU) admission, through a mediation analysis. In total, 1317 patients returned for a post COVID visit at a median of 2.6 (IQR 1.84-3.97) months after clinical recovery. WT was present in 69.6% of participants, followed by the Alpha (14.4%), Delta (8.9%), Gamma (3.9%) and Omicron strains (3.3%). Among patients with PCC, the most common manifestations were fatigue (51.7%), brain fog (32.7%) and respiratory symptoms (37.2%). Omicron vs. WT was associated with a reduced risk of PCC and PCC clusters; conversely, we observed a higher risk with the Delta and Alpha variants vs. WT. In total, 42% of the WT effect vs. Omicron on PCC risk appeared to be mediated by ICU admission. A reduced PCC risk was observed after Omicron infection, suggesting a possible reduction in the PCC burden over time. A non-negligible proportion of the variant effect on PCC risk seems mediated by increased disease severity during the acute disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3651-8923</Identifier><AffiliationInfo><Affiliation>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Science, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoro</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Science, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedberg</LastName><ForeName>Pontus</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3153-098X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, 17177 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavelli</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Icona Foundation, 20145 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Benedittis</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Icona Foundation, 20145 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Morais Caporali</LastName><ForeName>J&#xfa;lia Fonseca</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0003-0544-309X</Identifier><AffiliationInfo><Affiliation>School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinho</LastName><ForeName>Carolina Coimbra</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-0950-0322</Identifier><AffiliationInfo><Affiliation>School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Arnaldo Santos</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>School of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoro</LastName><ForeName>Maria Mercedes</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-6228-1114</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccherini Silberstein</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannetta</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6938-8627</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juozapait&#xe9;</LastName><ForeName>Dovil&#xe9;</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vilnius Santaros Klinikos Biobank, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strumiliene</LastName><ForeName>Edita</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, 03101 Vilnius, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0360-7011</Identifier><AffiliationInfo><Affiliation>Centro Universit&#xe1;rio de Lisboa Central, Centro Cl&#xed;nico Acad&#xe9;mico de Lisboa, 1169-050 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toscano</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro Hospitalar de Lisboa Ocidental, 1449-005 Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Qui&#xf1;ones</LastName><ForeName>Jes&#xfa;s Arturo</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3723-333X</Identifier><AffiliationInfo><Affiliation>Hospital Juan Graham Casasus, Villahermosa 86126, Tabasco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mommo</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>EuResist Network GEIE, 00152 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanti</LastName><ForeName>Iuri</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>EuResist Network GEIE, 00152 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Incardona</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7386-8551</Identifier><AffiliationInfo><Affiliation>EuResist Network GEIE, 00152 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>InformaPRO S.R.L., 00152 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozzi-Lepri</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6339-919X</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4498-4828</Identifier><AffiliationInfo><Affiliation>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Science, University of Milan, 20142 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EuCARE Project</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>European Union&#xb4;s Horizon Europe Research and Innovation Programme under Grant Agreement No 101046016</GrantID><Agency>Horizon 2020</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 viral variant</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">omicron variant</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">post acute sequelae of SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest related to this work to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339976</ArticleId><ArticleId IdType="pmc">PMC11437468</ArticleId><ArticleId IdType="doi">10.3390/v16091500</ArticleId><ArticleId IdType="pii">v16091500</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J. Infect. Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A., Shaar B.A., Almamlouk R., Riaz M., Obeidat M., Obeidat Y., Gerberi D., Taha R.M., et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022;28:657&#x2013;666. doi: 10.1016/j.cmi.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . Mayo Clinic Proceedings. Elsevier; Amsterdam, The Netherlands: 2020. Long-Term Effects of COVID-19. Centers for Disease Control and Prevention.</Citation></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. on behalf of the WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. Author Correction: Unexplained post-acute infection syndromes. Nat. Med. 2022;28:1723. doi: 10.1038/s41591-022-01952-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01952-7</ArticleId><ArticleId IdType="pubmed">35859204</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall-Gradisnik S., Eaton-Fitch N. Understanding myalgic encephalomyelitis. Science. 2022;377:1150&#x2013;1151. doi: 10.1126/science.abo1261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abo1261</ArticleId><ArticleId IdType="pubmed">36074854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J., Lin K., Zhang H., Xue Q., Zhu K., Yuan G., Sun Y., Zhu F., Ai J., Wang S., et al. A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China. Emerg. Microbes Infect. 2023;12:2220578. doi: 10.1080/22221751.2023.2220578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2220578</ArticleId><ArticleId IdType="pmc">PMC10281439</ArticleId><ArticleId IdType="pubmed">37272336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Li Y., Jiang Q., Jiang Y., Qin H. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis. J. Infect. 2024;89:106190. doi: 10.1016/j.jinf.2024.106190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2024.106190</ArticleId><ArticleId IdType="pubmed">38834107</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Topol E. Solving the puzzle of Long COVID. Science. 2024;383:830&#x2013;832. doi: 10.1126/science.adl0867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adl0867</ArticleId><ArticleId IdType="pubmed">38386747</ArticleId></ArticleIdList></Reference><Reference><Citation>Malden D.E., Liu I.A., Qian L., Sy L.S., Lewin B.J., Asamura D.T., Ryan D.S., Bezi C., Williams J.T.B., Kaiser R., et al. Post-COVID conditions following COVID-19 vaccination: A retrospective matched cohort study of patients with SARS-CoV-2 infection. Nat. Commun. 2024;15:4101. doi: 10.1038/s41467-024-48022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48022-9</ArticleId><ArticleId IdType="pmc">PMC11111703</ArticleId><ArticleId IdType="pubmed">38778026</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M., Mercad&#xe9;-Besora N., Kolde R., Trinh N.T.H., Roel E., Burn E., Rathod-Mistry T., Kostka K., Man W.Y., Delmestri A., et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: Staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir. Med. 2024;12:225&#x2013;236. doi: 10.1016/S2213-2600(23)00414-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H., Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790. doi: 10.1016/j.vaccine.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock M.D., Chew R.F., Preiss A.J., Hadley E.C., Redfield S., McMurry J.A., Leese P.J., Girvin A.T., Crosskey M., Zhou A.G., et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat. Commun. 2023;14:2914. doi: 10.1038/s41467-023-38388-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38388-7</ArticleId><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou G.N., Berry K., Rajeevan N., Li Y., Mutalik P., Yan L., Bui D., Cunningham F., Hynes D.M., Rowneki M., et al. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans: A Target Trial Emulation. Ann. Intern. Med. 2023;176:1486&#x2013;1497. doi: 10.7326/M23-1394.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1394</ArticleId><ArticleId IdType="pmc">PMC10620954</ArticleId><ArticleId IdType="pubmed">37903369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang M.H., Wu J.Y., Liu T.H., Hsu W.H., Tsai Y.W., Huang P.Y., Lai C.C. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J. Med. Virol. 2023;95:e28750. doi: 10.1002/jmv.28750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28750</ArticleId><ArticleId IdType="pubmed">37185834</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern. Med. 2023;183:554&#x2013;564. doi: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P., Naucl&#xe9;r P. Post-COVID-19 Condition After SARS-CoV-2 Infections During the Omicron Surge vs the Delta, Alpha, and Wild Type Periods in Stockholm, Sweden. J. Infect. Dis. 2024;229:133&#x2013;136. doi: 10.1093/infdis/jiad382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad382</ArticleId><ArticleId IdType="pmc">PMC10786247</ArticleId><ArticleId IdType="pubmed">37665981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Aceituno A., Garc&#xed;a-Hern&#xe1;ndez A., Larumbe-Zabala E. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Infect. Dis. Now. 2023;53:104688. doi: 10.1016/j.idnow.2023.104688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2023.104688</ArticleId><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="pubmed">36858287</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruijn S., van Hoek A.J., Mutubuki E.N., Knoop H., Slootweg J., Tulen A.D., Franz E., van den Wijngaard C.C., van der Maaden T. Lower prevalence of post-COVID-19 Condition following Omicron SARS-CoV-2 infection. Heliyon. 2024;10:e28941. doi: 10.1016/j.heliyon.2024.e28941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e28941</ArticleId><ArticleId IdType="pmc">PMC11015416</ArticleId><ArticleId IdType="pubmed">38617937</ArticleId></ArticleIdList></Reference><Reference><Citation>Thi Khanh H.N., Cornelissen L., Castanares-Zapatero D., De Pauw R., Van Cauteren D., Demarest S., Drieskens S., Devleesschauwer B., De Ridder K., Charafeddine R., et al. Association between SARS-CoV-2 variants and post COVID-19 condition: Findings from a longitudinal cohort study in the Belgian adult population. BMC Infect. Dis. 2023;23:774. doi: 10.1186/s12879-023-08787-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08787-8</ArticleId><ArticleId IdType="pmc">PMC10634063</ArticleId><ArticleId IdType="pubmed">37940843</ArticleId></ArticleIdList></Reference><Reference><Citation>Diexer S., Klee B., Gottschick C., Xu C., Broda A., Purschke O., Binder M., Frese T., Girndt M., Hoell J.I., et al. Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Int. J. Infect. Dis. 2023;136:14&#x2013;21. doi: 10.1016/j.ijid.2023.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.08.019</ArticleId><ArticleId IdType="pubmed">37634619</ArticleId></ArticleIdList></Reference><Reference><Citation>Babicki M., Ko&#x142;at D., Ka&#x142;uzi&#x144;ska-Ko&#x142;at &#x17b;., Kapusta J., Mastalerz-Migas A., Jankowski P., Chudzik M. The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period. Pathogens. 2024;13:267. doi: 10.3390/pathogens13030267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens13030267</ArticleId><ArticleId IdType="pmc">PMC10975347</ArticleId><ArticleId IdType="pubmed">38535610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert C.R., Strahm C., G&#xfc;sewell S., Cusini A., Brucher A., Goppel S., M&#xf6;ller E., M&#xf6;ller J.C., Ortner M., Ruetti M., et al. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. Clin. Infect. Dis. 2023;77:194&#x2013;202. doi: 10.1093/cid/ciad143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad143</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Notarte K.I., Peligro P.J., Velasco J.V., Ocampo M.J., Henry B.M., Arendt-Nielsen L., Torres-Macho J., Plaza-Manzano G. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature. Viruses. 2022;14:2629. doi: 10.3390/v14122629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122629</ArticleId><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G., McCann K., O&#x2019;Brien C., O&#x2019;Broin C., Tinago W., Yousif O., O&#x2019;Gorman T., Cotter A.G., Lambert J.S., Feeney E.R., et al. Impact of vaccination and variants of concern on long COVID clinical phenotypes. BMC Infect. Dis. 2023;23:804. doi: 10.1186/s12879-023-08783-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08783-y</ArticleId><ArticleId IdType="pmc">PMC10655269</ArticleId><ArticleId IdType="pubmed">37974068</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVries A., Shambhu S., Sloop S., Overhage J.M. One-Year Adverse Outcomes Among US Adults With Post-COVID-19 Condition vs Those Without COVID-19 in a Large Commercial Insurance Database. JAMA Health Forum. 2023;4:e230010. doi: 10.1001/jamahealthforum.2023.0010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2023.0010</ArticleId><ArticleId IdType="pmc">PMC9984976</ArticleId><ArticleId IdType="pubmed">36867420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P., Varisco B., Bai F., S&#xf6;nnerborg A., Naucler P., Pfeifer N., Cozzi-Lepri A., Ceccherini-Silberstein F., Naumovas D., Drobniewski F., et al. EuCARE-hospitalised study protocol: A cohort study of patients hospitalised with COVID-19 in the EuCARE project. BMC Infect. Dis. 2023;23:690. doi: 10.1186/s12879-023-08658-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08658-2</ArticleId><ArticleId IdType="pmc">PMC10580565</ArticleId><ArticleId IdType="pubmed">37845624</ArticleId></ArticleIdList></Reference><Reference><Citation>Varisco B., Bai F., De Benedittis S., Tavelli A., Cozzi-Lepri A., Sala M., Miraglia F.G., Santoro M.M., Ceccherini-Silberstein F., Shimoni Y., et al. EuCARE-POSTCOVID Study: A multicentre cohort study on long-term post-COVID-19 manifestations. BMC Infect. Dis. 2023;23:684. doi: 10.1186/s12879-023-08595-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08595-0</ArticleId><ArticleId IdType="pmc">PMC10576381</ArticleId><ArticleId IdType="pubmed">37833640</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Global COVID-19 Clinical Platform Case Report Form (CRF) for Post COVID Condition (Post COVID-19 CRF). 9 February 2021, Updated on 25 February 2021.  [(accessed on 13 December 2021)].  Available online:  https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-)</Citation></Reference><Reference><Citation>Gentilotti E., G&#xf3;rska A., Tami A., Gusinow R., Mirandola M., Rodr&#xed;guez Ba&#xf1;o J., Palacios Baena Z.R., Rossi E., Hasenauer J., Lopes-Rafegas I., et al. Clinical phenotypes and quality of life to define post-COVID-19 syndrome: A cluster analysis of the multinational, prospective ORCHESTRA cohort. EClinicalMedicine. 2023;62:102107. doi: 10.1016/j.eclinm.2023.102107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102107</ArticleId><ArticleId IdType="pmc">PMC10466236</ArticleId><ArticleId IdType="pubmed">37654668</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.T., Blau H., Casiraghi E., Bergquist T., Loomba J.J., Callahan T.J., Laraway B., Antonescu C., Coleman B., Gargano M., et al. Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413. doi: 10.1016/j.ebiom.2022.104413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104413</ArticleId><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas L.S., Molteni E., Deng J., Sudre C.H., Murray B., Kerfoot E., Antonelli M., Rjoob K., Capdevila Pujol J., Polidori L., et al. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: A prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. Lancet Digit. Health. 2023;5:e421&#x2013;e434. doi: 10.1016/S2589-7500(23)00056-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(23)00056-0</ArticleId><ArticleId IdType="pmc">PMC10187990</ArticleId><ArticleId IdType="pubmed">37202336</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbe S., Buckland-Merrett G. Data, disease and diplomacy: GISAID&#x2019;s innovative contribution to global health. Glob. Chall. 2017;1:33&#x2013;46. doi: 10.1002/gch2.1018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gch2.1018</ArticleId><ArticleId IdType="pmc">PMC6607375</ArticleId><ArticleId IdType="pubmed">31565258</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., et al. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Buse J.B., Liebovitz D.M., Nicklas J.M., Puskarich M.A., Cohen K., Belani H.K., Anderson B.J., Huling J.D., Tignanelli C.J., et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): A multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect. Dis. 2023;23:1119&#x2013;1129. doi: 10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M.L., King S., Pouwels K.B., Glickman M., Nafilyan V., Zaccardi F., Khunti K., Alwan N.A., Walker A.S. Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study. Open Forum Infect. Dis. 2022;9:ofac464. doi: 10.1093/ofid/ofac464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka S., Tsuzuki S., Suzuki M., Terada M., Akashi M., Osanai Y., Kuge C., Sanada M., Tanaka K., Maruki T., et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J. Infect. Chemother. 2022;28:1546&#x2013;1551. doi: 10.1016/j.jiac.2022.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.08.007</ArticleId><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="pubmed">35963600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Kaufmann M., Amati R., Frei A., von Wyl V., Fehr J.S., Albanese E., Puhan M.A. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PLoS ONE. 2023;18:e0281429. doi: 10.1371/journal.pone.0281429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281429</ArticleId><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier H.E., Kowalski-Dobson T., Eckard A., Gherasim C., Manthei D., Meyers A., Davis D., Bakker K., Lindsey K., Chu Z., et al. Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults. Open Forum Infect. Dis. 2024;11:ofae039. doi: 10.1093/ofid/ofae039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofae039</ArticleId><ArticleId IdType="pmc">PMC10847810</ArticleId><ArticleId IdType="pubmed">38328496</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K., Kristoffersen D.T., Dell&#x2019;Isola A., Kiadaliri A., Turkiewicz A., Runhaar J., Bierma-Zeinstra S., Englund M., Magnus P.M., Kinge J.M. Post-COVID medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat. Commun. 2022;13:7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M., Graziani L., Tilli M., Nkurunziza J., Vellere I., Borchi B., Mencarini J., Campolmi I., Gori L., Giovannoni L., et al. Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes. Viruses. 2022;14:2367. doi: 10.3390/v14112367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112367</ArticleId><ArticleId IdType="pmc">PMC9698829</ArticleId><ArticleId IdType="pubmed">36366465</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen K.H., Bao Y., Mortazavi J., Allen J.D., Chocano-Bedoya P.O., Corlin L. Prevalence and Factors Associated with Long COVID Symptoms among U.S. Adults, 2022. Vaccines. 2024;12:99. doi: 10.3390/vaccines12010099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12010099</ArticleId><ArticleId IdType="pmc">PMC10820629</ArticleId><ArticleId IdType="pubmed">38250912</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Pe&#xf1;as C., Notarte K.I., Macasaet R., Velasco J.V., Catahay J.A., Ver A.T., Chung W., Valera-Calero J.A., Navarro-Santana M. Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis. J. Infect. 2024;88:77&#x2013;88. doi: 10.1016/j.jinf.2023.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.12.004</ArticleId><ArticleId IdType="pubmed">38101521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M., Initiative L.C.R. Persistence of somatic symptoms after COVID-19 in the Netherlands: An observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., M&#xfc;ller B., Merle U. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin. Infect. Dis. 2022;74:1191&#x2013;1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.T., Porcher R., Pane I., Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat. Commun. 2022;13:1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing Long COVIC in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2020;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S., Abbafati C., Aerts J.G., Al-Aly Z., Ashbaugh C., Ballouz T., Blyuss O., Bobkova P., Bonsel G., Borzakova S., et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman L., Bested A.C., Bonilla H.F., Chheda B.V., Chu L., Curtin J.M., Dempsey T.T., Dimmock M.E., Dowell T.G., Felsenstein D., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin. Proc. 2021;96:2861&#x2013;2878. doi: 10.1016/j.mayocp.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.07.004</ArticleId><ArticleId IdType="pubmed">34454716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L., Authier F.J., Scheibenbogen C., Lorusso L., Helland I.B., Martin J.A., Sirbu C.A., Mengshoel A.M., Polo O., Behrends U., et al. European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe. Medicina. 2021;57:510. doi: 10.3390/medicina57050510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050510</ArticleId><ArticleId IdType="pmc">PMC8161074</ArticleId><ArticleId IdType="pubmed">34069603</ArticleId></ArticleIdList></Reference><Reference><Citation>Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management. National Institute for Health and Care Excellence (NICE); London, UK: 2021. Bookshelf ID: NBK579533.</Citation></Reference><Reference><Citation>Deumer U.S., Varesi A., Floris V., Savioli G., Mantovani E., L&#xf3;pez-Carrasco P., Rosati G.M., Prasad S., Ricevuti G. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview. J. Clin. Med. 2021;10:4786. doi: 10.3390/jcm10204786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10204786</ArticleId><ArticleId IdType="pmc">PMC8538807</ArticleId><ArticleId IdType="pubmed">34682909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., Steinbeis F., Haffke M., Rudolf G., Heidecker B., et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat. Commun. 2022;13:5104. doi: 10.1038/s41467-022-32507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi N., Liu K., Kawakami D., Kawai Y., Morisawa T., Nishida T., Sumita H., Unoki T., Hifumi T., Iida Y., et al. Post-Intensive Care Syndrome and Its New Challenges in Coronavirus Disease 2019 (COVID-19) Pandemic: A Review of Recent Advances and Perspectives. J. Clin. Med. 2021;10:3870. doi: 10.3390/jcm10173870.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173870</ArticleId><ArticleId IdType="pmc">PMC8432235</ArticleId><ArticleId IdType="pubmed">34501316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>